Latest article
Lilly’s tirzepatide beats Ozempic in head-to-head kind 2 diabetes trial
Eli Lilly announced that its investigated GIP and GLP-1 inhibitor tirzepatide has demonstrated superiority over Novo Nordisk's Ozempic in a Phase III study.The SURPASS-2...
Utah’s governor highlighted a controversial essential-oil MLM as a method to defend faculty youngsters...
Áine Cain 09/28/2021, 4:28 pm
According to Vote Smart, the governor of Utah will receive over $ 10,000 ($ 13,725) from doTerra International in 2020....
Desk-bound with diabetes | Mirage Information
Tied to a desk with diabetes? The study tests the effectiveness of a sedentary interventionAn innovative study in Melbourne enables desk workers with...